10x Genomics: Visium, NanoString Tech & Future of Single-Cell Analysis
Former Sales Manager at 10x Genomics
inpractise.com/articles/10x-genomics-visium-nanostring-technologies-and-future-of-single-cell-analysis
Former Sales Manager at 10x Genomics
The executive has over 20 years of experience in life science research. After spending over a decade in academic research roles, the executive has worked in sales roles for manufacturer of research equipment.
Interview Transcript
This is a snippet of the transcript, sign up to read more.
We are generalist investors and don't have a specialty in the life sciences. We've been learning about life sciences companies who were high fliers, but backed off in the stock market. We are specifically focusing on companies where there's a degree to which they could place an instrument then get aftermarket recurring revenue. It is easier for us to understand the core razor blade business model. One of the companies we've been working on is 10x Genomics. We've done our dive on the company we feel more comfortable about their position in single cell than spatial, though we need to believe in the spatial opportunity to invest. Those are the companies we look for and what brought us to this conversation today.
10x announced yesterday they have a road-map for 5,000, but didn't provide any data or timeline, whereas NanoString have a tested product with data. Other companies don't have single cell like 10x, so they have nothing to lose. All they need to do is capture the market 10x created by developing the spatial market. 10x enjoyed a lifetime of monopoly in single cell, growing exponentially from 10 million to more than half a billion. Their biggest problem will be their customers switching from single cell to spatial, and they don't care whether they use 10x or Illumina. If research demands you need spatial information to study cancer and treat patients better, they will simply switch. 10x are still promoting single cell using Chromium which gives the whole transcriptome, but it lacks spatial context.
This is a snippet of the transcript, sign up to read more.
We are generalist investors and don't have a specialty in the life sciences. We've been learning about life sciences companies who were high fliers, but backed off in the stock market. We are specifically focusing on companies where there's a degree to which they could place an instrument then get aftermarket recurring revenue. It is easier for us to understand the core razor blade business model. One of the companies we've been working on is 10x Genomics. We've done our dive on the company we feel more comfortable about their position in single cell than spatial, though we need to believe in the spatial opportunity to invest. Those are the companies we look for and what brought us to this conversation today.
Visium gives multicellular spatial on a glass FFP slide, and if you pick the genes you are interested in, that gives you the biological insight. Xenium is a custom design which can validate up to 380 genes. If a company offers 6,000 genes in tissue in a single experiment, you mount the slide on Monday and get 6,000 genes of data per every single cell by Friday for a million cells, for a few thousand dollars, why would anyone do single cells, validate in multicellular on tissue with the Visium, then go to the Xenium to validate a subset of genes?
This is a snippet of the transcript, sign up to read more.
Related Content
Copyright Notice
This document may not be reproduced, distributed, or transmitted in any form or by any means including resale of any part, unauthorised distribution to a third party or other electronic methods, without the prior written permission of IP 1 Ltd.
IP 1 Ltd, trading as In Practise (herein referred to as "IP") is a company registered in England and Wales and is not a registered investment advisor or broker-dealer, and is not licensed nor qualified to provide investment advice.
In Practise reserves all copyright, intellectual and other property rights in the Content. The information published in this transcript (“Content”) is for information purposes only and should not be used as the sole basis for making any investment decision. Information provided by IP is to be used as an educational tool and nothing in this Content shall be construed as an offer, recommendation or solicitation regarding any financial product, service or management of investments or securities. The views of the executive expressed in the Content are those of the expert and they are not endorsed by, nor do they represent the opinion of In Practise. In Practise makes no representations and accepts no liability for the Content or for any errors, omissions, or inaccuracies will in no way be held liable for any potential or actual violations of laws, including without limitation any securities laws, based on Information sent to you by In Practise.
© 2024 IP 1 Ltd. All rights reserved.